Clinical Trial

Effects of Dexmedetomidine in Patients With Agitated Delirium in Palliative Care

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated April 15, 2025 (before its estimated January 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this multi-centre phase I/II open-label, single-arm study is to determine the feasibility, optimal dose, and preliminary efficacy of dexmedetomidine to manage agitated delirium among patients near the end of life followed by a palliative care provider in a non-monitored setting. Fifty patients will receive dexmedetomidine (0.4 mcg/kg/hour, titrated up to 1.0 mcg/kg/hour) subcutaneously. Feasibility (recruitment rate, cost), safety (rate of adverse events), dosing, and preliminary efficacy (agitation, delirium severity) will be measured.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2021-03-30; most recent amendment 2025-04-11.
Status change: Not Yet Recruiting → Recruiting 2022-12-16
Trial Details
NCT Number NCT04824144
Lead Sponsor Bruyère Health Research Institute.
Collaborators: The Ottawa Hospital, Bruyère Continuing Care, Foothills Medical Centre
Conditions Hyperactive Delirium, Delirium of Mixed Origin
Enrollment 50 participants
Start Date 2024-01-30
Primary Completion 2026-01-31 (estimated)
Study Completion 2026-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-04-15